Oragenics (OGEN) announced that it has regained full compliance with NYSE American’s continued listing standards and is positioning the company to focus exclusively on advancing its lead clinical program.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN:
- Oragenics, Receptor.AI partner to accelerate pipeline development
- Oragenics Appoints Natasha Giordano to Board of Directors